Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1993;24:1681-1685

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasaka, M.
Right arrow Articles by Omae, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasaka, M.
Right arrow Articles by Omae, T.

Stroke, Vol 24, 1681-1685, Copyright © 1993 by American Heart Association


ARTICLES

Clinical features of recurrent embolization in acute cardioembolic stroke

M Yasaka, T Yamaguchi, J Oita, T Sawada, M Shichiri and T Omae
Department of Medicine, National Cardiovascular Center, Osaka, Japan.

BACKGROUND AND PURPOSE: Recurrent embolization is a serious problem in acute cardioembolic stroke. However, the clinical features and predisposing factors of recurrent embolization have not been fully elucidated. METHODS: Subjects were 227 consecutive patients (128 men and 99 women, aged 68.6 +/- 13.2 years) with acute cardioembolic stroke who did not receive anticoagulant therapy during the first 14 days after stroke onset. We assigned the subjects to two groups according to the occurrence or nonoccurrence of recurrent attacks within 14 days of the stroke onset. We assessed their clinical features, coagulation study results, and underlying heart disease. RESULTS: Recurrent brain or systemic embolization during the first 14 days after onset was noted in 46 patients (20.3%, group A) but not in the other 181 (group B). Recurrent embolization was more frequently noted at an early phase than at a late phase during the initial 14 days. Mortality was higher in group A (19.6%) than in group B (8.8%). The mean plasma level of antithrombin III (77.8 +/- 19.5%) at admission in group A patients was significantly lower than that in group B patients (87.9 +/- 15.5%). After admission, hematocrit decreased in group B patients but slightly increased in group A patients, in whom diuretics were more commonly used. Rheumatic heart disease and prosthetic valves, in addition to the presence of intracardiac thrombi, were seen more commonly in group A patients, whereas atrial fibrillation without organic heart disease and myocardial infarction were more frequent in group B patients. CONCLUSIONS: Low plasma levels of antithrombin III, dehydration, the use of diuretics, and the presence of rheumatic heart disease, prosthetic valves, and intracardiac thrombi seem to be predisposing factors for recurrent embolization. Immediate anticoagulation may be considered in acute cardioembolic stroke patients if such predisposing factors are demonstrated.


This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Hata, Y Tanizaki, Y Kiyohara, I Kato, M Kubo, K Tanaka, K Okubo, H Nakamura, Y Oishi, S Ibayashi, et al.
Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study
J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 368 - 372.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Kamath, A D Blann, B S P Chin, and G Y H Lip
Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation
Heart, September 1, 2003; 89(9): 1093 - 1095.
[Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. Chan, S. F. Knutsen, G. G. Blix, J. W. Lee, and G. E. Fraser
Water, Other Fluids, and Fatal Coronary Heart Disease: The Adventist Health Study
Am. J. Epidemiol., May 1, 2002; 155(9): 827 - 833.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Chest, January 1, 2001; 119(1_suppl): 300S - 320S.
[Full Text] [PDF]


Home page
StrokeHome page
A. G. Dyker and K. R. Lees
Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke, February 1, 1998; 29(2): 535 - 542.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
V. L. Babikian, C. A. C. Wijman, C. Hyde, N. L. Cantelmo, M. R. Winter, E. Baker, and V. Pochay
Cerebral Microembolism and Early Recurrent Cerebral or Retinal Ischemic Events
Stroke, July 1, 1997; 28(7): 1314 - 1318.
[Abstract] [Full Text]


Home page
StrokeHome page
U. Sliwka, A. Lingnau, W.-D. Stohlmann, P. Schmidt, M. Mull, R. R. Diehl, and J. Noth
Prevalence and Time Course of Microembolic Signals in Patients With Acute Stroke: A Prospective Study
Stroke, February 1, 1997; 28(2): 358 - 363.
[Abstract] [Full Text]


Home page
StrokeHome page
A.M. Forteza, V.L. Babikian, C. Hyde, M. Winter, and V. Pochay
Effect of Time and Cerebrovascular Symptoms on the Prevalence of Microembolic Signals in Patients With Cervical Carotid Stenosis
Stroke, April 1, 1996; 27(4): 687 - 690.
[Abstract] [Full Text]